Results showed that the greatest tumor response rates were seen in mast cell tumors (MCT) and that dogs with MCT possessing KIT mutations were much more likely to respond to therapy than those tumors with wild-type KIT. The gene discussed is KIT; the disease is mast cell neoplasm.